Global Alopecia Treatment Market Research Report 2019 to 2025 provides a unique tool for evaluating the market, highlighting opportunities, and supporting strategic and tactical decision-making. This report recognizes that in this rapidly-evolving and competitive environment, up-to-date marketing information is essential to monitor performance and make critical decisions for growth and profitability.
The global alopecia treatment market size was valued at US$ 7.4 Bn in 2018, and is expected to witness a CAGR of 5.6% over the forecast period (2019 – 2025).
Alopecia also called as hair-loss or baldness is a medical condition that refers to loss of hairs from head or any part of the body. The condition can occur in both male and female and at any age. There are five major type of alopecia namely; alopecia areata, androgenic alopecia, ciatricial alopecia, traction alopecia, and alopecia totalis. Alopecia areata is a common autoimmune disorder in which the immune system of body attacks the healthy hair follicle leading to hair fall. Androgenic alopecia also known as male pattern baldness and female pattern hair loss is a very common type of alopecia and affects many individuals at some stage of life. Ciatricial alopecia also known as scarring alopecia is a condition in which hair follicles are destroyed and replaced by scar tissue. There are only few approved treatment drugs indicated for the treatment of alopecia. For instance, Minoxidil, Finasteride, and Cyclosporine.
Top manufacturers of Alopecia Treatment Market are: Teva Pharmaceutical Industries, Merck, Johnson_Johnson, Reddy’s Laboratories, Cipla, Cellmid, Himalaya Drug, Taisho Pharmaceutical Holdings and others.
